BioNTech CEO Says 'Highly Likely' Vaccine Is Effective Against U.K. Virus Variant

NPR

22 Dec 2020 0 shares 1 views

BioNTech CEO Says 'Highly Likely' Vaccine Is Effective Against U.K. Virus Variant

NPR

Published 22 Dec 2020

"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," BioNTech CEO Ugur Sahin said Tuesday.

Full Article

Related news coverage

America’s Deadliest Year, In Numbers – OpEd

Eurasia Review 30 Dec 2020

This year, more than any other in recent memory, we experienced a public health emergency in the shape of charts and data which..

It is just 70 per cent effective against novel coronavirus
Mid-Day 31 Dec 2020
No travel history in 1st reported US case of virus variant
SeattlePI.com 30 Dec 2020
No travel history in 1st reported US case of virus variant
SeattlePI.com 30 Dec 2020
AstraZeneca: Shot will be effective against COVID-19 variant
SeattlePI.com 27 Dec 2020

More coverage

AstraZeneca: Shot will be effective against COVID-19 variant

SeattlePI.com 27 Dec 2020

LONDON (AP) — The head of drugmaker AstraZeneca, which is developing a coronavirus vaccine widely expected to be approved by U.K...

New COVID-19 virus strain likely evolved in UK
Mid-Day 23 Dec 2020
Coronavirus digest: AstraZeneca vaccine likely effective against new variant
Deutsche Welle 23 Dec 2020
BioNTech says its highly likely its COVID-19 vaccine can handle mutation
Sydney Morning Herald 22 Dec 2020
BioNTech says it is highly likely its COVID-19 vaccine can handle mutation
Brisbane Times 22 Dec 2020

BioNTech CEO Says 'Highly Likely' Vaccine Is Effective Against U.K. Virus Variant

BioNTech CEO Says 'Highly Likely' Vaccine Is Effective Against U.K. Virus Variant

You might like

Related news coverage

America’s Deadliest Year, In Numbers – OpEd

Advertisement

More coverage

AstraZeneca: Shot will be effective against COVID-19 variant